Skip to main content
Top

Open Access 17-06-2024 | Myocardial Infarction | Invited Review Article

No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis

Authors: Yuichi Saito, Kenichi Tsujita, Yoshio Kobayashi

Published in: Cardiovascular Intervention and Therapeutics

Login to get access

Abstract

Standard modifiable cardiovascular risk factors (SMuRFs), such as hypertension, diabetes, dyslipidemia, and current smoking, are associated with the development of atherosclerotic cardiovascular diseases including acute myocardial infarction (MI). Thus, therapeutic approaches against SMuRFs are important as primary and secondary prevention of cardiovascular diseases. In patients with acute MI, however, the prognosis is counterintuitively poor when SMuRFs are lacking. The growing evidence has explored the prevalence, pathophysiology, and prognosis of SMuRF-less patients in acute MI and suggested the potential underlying mechanisms. This review article summarizes the clinical evidence and relevance of the lack of SMuRFs in acute MI.
Literature
1.
go back to reference Saito I, Yamagishi K, Kokubo Y, Yatsuya H, Iso H, Sawada N, et al. Impact of cardiovascular disease on the death certificate diagnosis of heart failure, ischemic heart disease, and cerebrovascular disease—The Japan Public Health Center-based prospective study. Circ J. 2023;87:1196–202.CrossRefPubMed Saito I, Yamagishi K, Kokubo Y, Yatsuya H, Iso H, Sawada N, et al. Impact of cardiovascular disease on the death certificate diagnosis of heart failure, ischemic heart disease, and cerebrovascular disease—The Japan Public Health Center-based prospective study. Circ J. 2023;87:1196–202.CrossRefPubMed
2.
go back to reference Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121:677–94.CrossRefPubMed Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121:677–94.CrossRefPubMed
3.
go back to reference GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100–32.CrossRef GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100–32.CrossRef
4.
go back to reference Walli-Attaei M, Rosengren A, Rangarajan S, Breet Y, Abdul-Razak S, Sharief WA, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet. 2022;400:811–21.CrossRefPubMed Walli-Attaei M, Rosengren A, Rangarajan S, Breet Y, Abdul-Razak S, Sharief WA, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet. 2022;400:811–21.CrossRefPubMed
5.
go back to reference Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389:1273–85.PubMedCentralCrossRefPubMed Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389:1273–85.PubMedCentralCrossRefPubMed
6.
go back to reference Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K, et al. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. Circ J. 2022;86:882–915.CrossRefPubMed Nakano S, Kohsaka S, Chikamori T, Fukushima K, Kobayashi Y, Kozuma K, et al. JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease. Circ J. 2022;86:882–915.CrossRefPubMed
7.
go back to reference Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.CrossRefPubMed Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.CrossRefPubMed
8.
go back to reference Nohara A. The worst combination for coronary artery disease under strong-statin therapy is chronic kidney disease and diabetes—non-lipid residual risk assessment from the REAL-CAD study. Circ J. 2024;88:1004–6.CrossRefPubMed Nohara A. The worst combination for coronary artery disease under strong-statin therapy is chronic kidney disease and diabetes—non-lipid residual risk assessment from the REAL-CAD study. Circ J. 2024;88:1004–6.CrossRefPubMed
9.
go back to reference Roe MT, Halabi AR, Mehta RH, Chen AY, Newby LK, Harrington RA, et al. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007;153:507–14.CrossRefPubMed Roe MT, Halabi AR, Mehta RH, Chen AY, Newby LK, Harrington RA, et al. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007;153:507–14.CrossRefPubMed
10.
go back to reference Nauta ST, Deckers JW, van der Boon RM, Akkerhuis KM, van Domburg RT. Risk factors for coronary heart disease and survival after myocardial infarction. Eur J Prev Cardiol. 2014;21:576–83.CrossRefPubMed Nauta ST, Deckers JW, van der Boon RM, Akkerhuis KM, van Domburg RT. Risk factors for coronary heart disease and survival after myocardial infarction. Eur J Prev Cardiol. 2014;21:576–83.CrossRefPubMed
11.
go back to reference Wang JY, Goodman SG, Saltzman I, Wong GC, Huynh T, Dery JP, et al. Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the canadian global registry of acute coronary events. Can J Cardiol. 2015;31:1455–61.CrossRefPubMed Wang JY, Goodman SG, Saltzman I, Wong GC, Huynh T, Dery JP, et al. Cardiovascular risk factors and in-hospital mortality in acute coronary syndromes: insights from the canadian global registry of acute coronary events. Can J Cardiol. 2015;31:1455–61.CrossRefPubMed
12.
go back to reference Vernon ST, Coffey S, Bhindi R, Soo Hoo SY, Nelson GI, Ward MR, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017;24:1824–30.CrossRefPubMed Vernon ST, Coffey S, Bhindi R, Soo Hoo SY, Nelson GI, Ward MR, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017;24:1824–30.CrossRefPubMed
13.
go back to reference Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, et al. Cardiovascular risk and statin eligibility of young adults after an MI: partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292–302.CrossRefPubMed Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, et al. Cardiovascular risk and statin eligibility of young adults after an MI: partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71:292–302.CrossRefPubMed
14.
go back to reference Vernon ST, Coffey S, D’Souza M, Chow CK, Kilian J, Hyun K, et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors—how common are they, and what are their outcomes? J Am Heart Assoc. 2019;8: e013296.PubMedCentralCrossRefPubMed Vernon ST, Coffey S, D’Souza M, Chow CK, Kilian J, Hyun K, et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors—how common are they, and what are their outcomes? J Am Heart Assoc. 2019;8: e013296.PubMedCentralCrossRefPubMed
15.
go back to reference Figtree GA, Vernon ST, Hadziosmanovic N, Sundstrom J, Alfredsson J, Arnott C, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397:1085–94.CrossRefPubMed Figtree GA, Vernon ST, Hadziosmanovic N, Sundstrom J, Alfredsson J, Arnott C, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397:1085–94.CrossRefPubMed
16.
go back to reference Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Takeji Y, Yamaji K, et al. Coronary artery disease without standard cardiovascular risk factors. Am J Cardiol. 2022;164:34–43.CrossRefPubMed Yamamoto K, Natsuaki M, Morimoto T, Shiomi H, Takeji Y, Yamaji K, et al. Coronary artery disease without standard cardiovascular risk factors. Am J Cardiol. 2022;164:34–43.CrossRefPubMed
17.
go back to reference Figtree GA, Redfors B, Kozor R, Vernon ST, Grieve SM, Mazhar J, et al. Clinical outcomes in patients with ST-segment elevation MI and no standard modifiable cardiovascular risk factors. JACC Cardiovasc Interv. 2022;15:1167–75.CrossRefPubMed Figtree GA, Redfors B, Kozor R, Vernon ST, Grieve SM, Mazhar J, et al. Clinical outcomes in patients with ST-segment elevation MI and no standard modifiable cardiovascular risk factors. JACC Cardiovasc Interv. 2022;15:1167–75.CrossRefPubMed
18.
go back to reference Sia CH, Ko J, Zheng H, Ho AF, Foo D, Foo LL, et al. Comparison of mortality outcomes in acute myocardial infarction patients with or without standard modifiable cardiovascular risk factors. Front Cardiovasc Med. 2022;9: 876465.PubMedCentralCrossRefPubMed Sia CH, Ko J, Zheng H, Ho AF, Foo D, Foo LL, et al. Comparison of mortality outcomes in acute myocardial infarction patients with or without standard modifiable cardiovascular risk factors. Front Cardiovasc Med. 2022;9: 876465.PubMedCentralCrossRefPubMed
19.
go back to reference Moledina SM, Rashid M, Nolan J, Nakao K, Sun LY, Velagapudi P, et al. Addressing disparities of care in non-ST-segment elevation myocardial infarction patients without standard modifiable risk factors: insights from a nationwide cohort study. Eur J Prev Cardiol. 2022;29:1084–92.CrossRefPubMed Moledina SM, Rashid M, Nolan J, Nakao K, Sun LY, Velagapudi P, et al. Addressing disparities of care in non-ST-segment elevation myocardial infarction patients without standard modifiable risk factors: insights from a nationwide cohort study. Eur J Prev Cardiol. 2022;29:1084–92.CrossRefPubMed
20.
go back to reference Suzuki S, Saito Y, Yamashita D, Matsumoto T, Sato T, Wakabayashi S, et al. Clinical characteristics and prognosis of patients with no standard modifiable risk factors in acute myocardial infarction. Heart Lung Circ. 2022;31:1228–33.CrossRefPubMed Suzuki S, Saito Y, Yamashita D, Matsumoto T, Sato T, Wakabayashi S, et al. Clinical characteristics and prognosis of patients with no standard modifiable risk factors in acute myocardial infarction. Heart Lung Circ. 2022;31:1228–33.CrossRefPubMed
21.
go back to reference Figtree GA, Vernon ST, Hadziosmanovic N, Sundstrom J, Alfredsson J, Nicholls SJ, et al. Mortality and cardiovascular outcomes in patients presenting with non-ST elevation myocardial infarction despite no standard modifiable risk factors: results from the SWEDEHEART registry. J Am Heart Assoc. 2022;11: e024818.PubMedCentralCrossRefPubMed Figtree GA, Vernon ST, Hadziosmanovic N, Sundstrom J, Alfredsson J, Nicholls SJ, et al. Mortality and cardiovascular outcomes in patients presenting with non-ST elevation myocardial infarction despite no standard modifiable risk factors: results from the SWEDEHEART registry. J Am Heart Assoc. 2022;11: e024818.PubMedCentralCrossRefPubMed
22.
go back to reference Kong G, Chew NWS, Ng CH, Chin YH, Zeng R, Foo R, et al. Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study of 5400 asian patients. J Thromb Thrombolysis. 2022;54:569–78.CrossRefPubMed Kong G, Chew NWS, Ng CH, Chin YH, Zeng R, Foo R, et al. Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study of 5400 asian patients. J Thromb Thrombolysis. 2022;54:569–78.CrossRefPubMed
23.
go back to reference Li S, Gao X, Yang J, Xu H, Wang Y, Zhao Y, et al. Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry. BMC Med. 2022;20:217.PubMedCentralCrossRefPubMed Li S, Gao X, Yang J, Xu H, Wang Y, Zhao Y, et al. Number of standard modifiable risk factors and mortality in patients with first-presentation ST-segment elevation myocardial infarction: insights from China Acute Myocardial Infarction registry. BMC Med. 2022;20:217.PubMedCentralCrossRefPubMed
24.
go back to reference Saito Y, Inohara T, Kohsaka S, Wada H, Takamisawa I, Yamaji K, et al. Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: insights from the nationwide Japanese percutaneous coronary intervention registry. Am Heart J. 2023;258:69–76.CrossRefPubMed Saito Y, Inohara T, Kohsaka S, Wada H, Takamisawa I, Yamaji K, et al. Characteristics and outcomes of patients with no standard modifiable risk factors undergoing primary revascularization for acute myocardial infarction: insights from the nationwide Japanese percutaneous coronary intervention registry. Am Heart J. 2023;258:69–76.CrossRefPubMed
25.
go back to reference Kelly C, Lan NSR, Phan J, Hng C, Matthews A, Rankin JM, et al. Characteristics and outcomes of young patients with ST-elevation myocardial infarction without standard modifiable risk factors. Am J Cardiol. 2023;202:81–9.CrossRefPubMed Kelly C, Lan NSR, Phan J, Hng C, Matthews A, Rankin JM, et al. Characteristics and outcomes of young patients with ST-elevation myocardial infarction without standard modifiable risk factors. Am J Cardiol. 2023;202:81–9.CrossRefPubMed
26.
go back to reference Sheikh S, Peerwani G, Hanif B, Virani S. Clinical characteristics, management, and 5-year survival compared between no standard modifiable risk factor (SMuRFless) and ≥ 1 SMuRF ACS cases: an analysis of 15,051 cases from Pakistan. BMC Cardiovasc Disord. 2023;23:320.PubMedCentralCrossRefPubMed Sheikh S, Peerwani G, Hanif B, Virani S. Clinical characteristics, management, and 5-year survival compared between no standard modifiable risk factor (SMuRFless) and ≥ 1 SMuRF ACS cases: an analysis of 15,051 cases from Pakistan. BMC Cardiovasc Disord. 2023;23:320.PubMedCentralCrossRefPubMed
27.
go back to reference Gonzalez-Del-Hoyo M, Rossello X, Peral V, Pocock S, Van de Werf F, Chin CT, et al. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: insights from an international cohort of 23,489 patients with acute coronary syndrome. Am Heart J. 2023;264:20–30.CrossRefPubMed Gonzalez-Del-Hoyo M, Rossello X, Peral V, Pocock S, Van de Werf F, Chin CT, et al. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: insights from an international cohort of 23,489 patients with acute coronary syndrome. Am Heart J. 2023;264:20–30.CrossRefPubMed
28.
go back to reference Sheikhy A, Fallahzadeh A, Jameie M, Aein A, Masoudkabir F, Maghsoudi M, et al. In-hospital and 1-year outcomes of patients without modifiable risk factors presenting with acute coronary syndrome undergoing PCI: a sex-stratified analysis. Front Cardiovasc Med. 2023;10:1235667.PubMedCentralCrossRefPubMed Sheikhy A, Fallahzadeh A, Jameie M, Aein A, Masoudkabir F, Maghsoudi M, et al. In-hospital and 1-year outcomes of patients without modifiable risk factors presenting with acute coronary syndrome undergoing PCI: a sex-stratified analysis. Front Cardiovasc Med. 2023;10:1235667.PubMedCentralCrossRefPubMed
29.
go back to reference Jang SJ, Kim LK, Sobti NK, Yeo I, Cheung JW, Feldman DN, et al. Mortality of patients with ST-segment-elevation myocardial infarction without standard modifiable risk factors among patients without known coronary artery disease: age-stratified and sex-related analysis from nationwide readmissions database 2010–2014. Am J Prev Cardiol. 2023;14: 100474.PubMedCentralCrossRefPubMed Jang SJ, Kim LK, Sobti NK, Yeo I, Cheung JW, Feldman DN, et al. Mortality of patients with ST-segment-elevation myocardial infarction without standard modifiable risk factors among patients without known coronary artery disease: age-stratified and sex-related analysis from nationwide readmissions database 2010–2014. Am J Prev Cardiol. 2023;14: 100474.PubMedCentralCrossRefPubMed
30.
go back to reference Justin Paul G, Sankaran S, Saminathan K, Iliyas M, Sethupathy S, Saravanan S, et al. Outcomes of ST segment elevation myocardial infarction without standard modifiable cardiovascular risk factors—newer insights from a prospective registry in India. Glob Heart. 2023;18:13.PubMedCentralPubMed Justin Paul G, Sankaran S, Saminathan K, Iliyas M, Sethupathy S, Saravanan S, et al. Outcomes of ST segment elevation myocardial infarction without standard modifiable cardiovascular risk factors—newer insights from a prospective registry in India. Glob Heart. 2023;18:13.PubMedCentralPubMed
31.
go back to reference Iwata J, Inohara T, Shiraishi Y, Nakamaru R, Niimi N, Ueda I, et al. Standard modifiable cardiovascular risk factors in patients with acute coronary syndrome: a report from multicenter percutaneous coronary intervention registry. J Cardiol. 2023;81:571–6.CrossRefPubMed Iwata J, Inohara T, Shiraishi Y, Nakamaru R, Niimi N, Ueda I, et al. Standard modifiable cardiovascular risk factors in patients with acute coronary syndrome: a report from multicenter percutaneous coronary intervention registry. J Cardiol. 2023;81:571–6.CrossRefPubMed
32.
go back to reference Zhao G, Zhou M, Zhao X, Ma C, Han Y, Liu J, et al. Characteristics, treatment, and in-hospital outcomes of older patients with stemi without standard modifiable risk factors. JACC Asia. 2024;4:73–83.CrossRefPubMed Zhao G, Zhou M, Zhao X, Ma C, Han Y, Liu J, et al. Characteristics, treatment, and in-hospital outcomes of older patients with stemi without standard modifiable risk factors. JACC Asia. 2024;4:73–83.CrossRefPubMed
33.
go back to reference Akase H, Okamura T, Nagoshi R, Fujimura T, Miyazaki Y, Takenaka H, et al. Risk assessment of side branch compromise after coronary bifurcation stenting—a substudy of the 3D-OCT bifurcation registry. Circ J. 2024;88:959–69.CrossRefPubMed Akase H, Okamura T, Nagoshi R, Fujimura T, Miyazaki Y, Takenaka H, et al. Risk assessment of side branch compromise after coronary bifurcation stenting—a substudy of the 3D-OCT bifurcation registry. Circ J. 2024;88:959–69.CrossRefPubMed
34.
go back to reference Akashi N, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, et al. Sex differences in long-term outcomes in patients with chronic coronary syndrome after percutaneous coronary intervention—insights from a Japanese real-world database using a storage system. Circ J. 2023;87:775–82.CrossRefPubMed Akashi N, Matoba T, Kohro T, Oba Y, Kabutoya T, Imai Y, et al. Sex differences in long-term outcomes in patients with chronic coronary syndrome after percutaneous coronary intervention—insights from a Japanese real-world database using a storage system. Circ J. 2023;87:775–82.CrossRefPubMed
35.
go back to reference Arai R, Okumura Y, Murata N, Fukamachi D, Honda S, Nishihira K, et al. Prevalence and impact of polyvascular disease in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention—insights from the Japan acute myocardial infarction registry (JAMIR). Circ J. 2024;88:911–20.CrossRefPubMed Arai R, Okumura Y, Murata N, Fukamachi D, Honda S, Nishihira K, et al. Prevalence and impact of polyvascular disease in patients with acute myocardial infarction in the contemporary era of percutaneous coronary intervention—insights from the Japan acute myocardial infarction registry (JAMIR). Circ J. 2024;88:911–20.CrossRefPubMed
36.
go back to reference Asada K, Saito Y, Sato T, Matsumoto T, Yamashita D, Suzuki S, et al. Prognostic value of natriuretic peptide levels and in-hospital heart failure events in patients with acute myocardial infarction. Circ J. 2023;87:640–7.CrossRefPubMed Asada K, Saito Y, Sato T, Matsumoto T, Yamashita D, Suzuki S, et al. Prognostic value of natriuretic peptide levels and in-hospital heart failure events in patients with acute myocardial infarction. Circ J. 2023;87:640–7.CrossRefPubMed
37.
go back to reference Feng X, Xu Y, Zeng M, Qin Y, Weng Z, Sun Y, et al. Optical coherence tomography assessment of coronary lesions associated with microvascular dysfunction in ST-segment elevation myocardial infarction. Circ J. 2023;87:1625–32.CrossRefPubMed Feng X, Xu Y, Zeng M, Qin Y, Weng Z, Sun Y, et al. Optical coherence tomography assessment of coronary lesions associated with microvascular dysfunction in ST-segment elevation myocardial infarction. Circ J. 2023;87:1625–32.CrossRefPubMed
38.
go back to reference Fujihara M, Tsukizawa T, Yazu Y, Tsujikawa S, Yokoi Y, Uesima D. Cost change of elective percutaneous coronary artery intervention for chronic coronary syndrome in Japan from 2010 to 2019. Circ J. 2023;87:767–74.CrossRefPubMed Fujihara M, Tsukizawa T, Yazu Y, Tsujikawa S, Yokoi Y, Uesima D. Cost change of elective percutaneous coronary artery intervention for chronic coronary syndrome in Japan from 2010 to 2019. Circ J. 2023;87:767–74.CrossRefPubMed
39.
go back to reference Fukui K, Takahashi J, Hao K, Honda S, Nishihira K, Kojima S, et al. Disparity of performance measure by door-to-balloon time between a rural and urban area for management of patients with ST-segment elevation myocardial infarction - insights from the nationwide Japan acute myocardial infarction registry. Circ J. 2023;87:648–56.CrossRefPubMed Fukui K, Takahashi J, Hao K, Honda S, Nishihira K, Kojima S, et al. Disparity of performance measure by door-to-balloon time between a rural and urban area for management of patients with ST-segment elevation myocardial infarction - insights from the nationwide Japan acute myocardial infarction registry. Circ J. 2023;87:648–56.CrossRefPubMed
40.
go back to reference Godo S, Yasuda S. New landscape of acute myocardial infarction complicated by cardiogenic shock with the advent of a small but mighty heart pump. Circ J. 2023;87:598–9.CrossRefPubMed Godo S, Yasuda S. New landscape of acute myocardial infarction complicated by cardiogenic shock with the advent of a small but mighty heart pump. Circ J. 2023;87:598–9.CrossRefPubMed
42.
go back to reference Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023;87:879–936.CrossRefPubMed Hokimoto S, Kaikita K, Yasuda S, Tsujita K, Ishihara M, Matoba T, et al. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction. Circ J. 2023;87:879–936.CrossRefPubMed
44.
go back to reference Ikeda Y, Ako J, Toda K, Hirayama A, Kinugawa K, Kobayashi Y, et al. Short-term outcomes of Impella support in japanese patients with cardiogenic shock due to acute myocardial infarction—Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD). Circ J. 2023;87:588–97.CrossRefPubMed Ikeda Y, Ako J, Toda K, Hirayama A, Kinugawa K, Kobayashi Y, et al. Short-term outcomes of Impella support in japanese patients with cardiogenic shock due to acute myocardial infarction—Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD). Circ J. 2023;87:588–97.CrossRefPubMed
45.
go back to reference Ishii H. Importance of the assessment of infarction size in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Circ J. 2022;86(12):1980–1.CrossRefPubMed Ishii H. Importance of the assessment of infarction size in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Circ J. 2022;86(12):1980–1.CrossRefPubMed
46.
go back to reference Ishii M, Nakamura T, Tsujita K. Intravascular imaging and coronary microvascular dysfunction after percutaneous coronary intervention in ST-segment elevation myocardial infarction. Circ J. 2023;87(11):1633–4.CrossRefPubMed Ishii M, Nakamura T, Tsujita K. Intravascular imaging and coronary microvascular dysfunction after percutaneous coronary intervention in ST-segment elevation myocardial infarction. Circ J. 2023;87(11):1633–4.CrossRefPubMed
48.
go back to reference Kikuchi M, Tahara Y, Yamaguchi J, Nakashima T, Nomura O, Tanaka A, et al. Executive summary—acute coronary syndrome in the Japan Resuscitation Council guidelines for resuscitation 2020. Circ J. 2023;87:866–78.CrossRefPubMed Kikuchi M, Tahara Y, Yamaguchi J, Nakashima T, Nomura O, Tanaka A, et al. Executive summary—acute coronary syndrome in the Japan Resuscitation Council guidelines for resuscitation 2020. Circ J. 2023;87:866–78.CrossRefPubMed
49.
go back to reference Kimura S, Isshiki A, Shimizu M, Fujii H, Suzuki M. Clinical significance of coronary healed plaques in stable angina pectoris patients undergoing percutaneous coronary intervention. Circ J. 2023;87:1643–53.CrossRefPubMed Kimura S, Isshiki A, Shimizu M, Fujii H, Suzuki M. Clinical significance of coronary healed plaques in stable angina pectoris patients undergoing percutaneous coronary intervention. Circ J. 2023;87:1643–53.CrossRefPubMed
50.
go back to reference Kitahara H. How can we prevent both bleeding and ischemic events after percutaneous coronary intervention in high-bleeding risk patients? Circ J. 2022;86:1362–4.CrossRefPubMed Kitahara H. How can we prevent both bleeding and ischemic events after percutaneous coronary intervention in high-bleeding risk patients? Circ J. 2022;86:1362–4.CrossRefPubMed
52.
go back to reference Moriwaki K, Kurita T, Hirota Y, Ito H, Ishise T, Fujimoto N, et al. Prognostic impact of prehospital simple risk index in patients with ST-elevation myocardial infarction. Circ J. 2023;87:629–39.CrossRefPubMed Moriwaki K, Kurita T, Hirota Y, Ito H, Ishise T, Fujimoto N, et al. Prognostic impact of prehospital simple risk index in patients with ST-elevation myocardial infarction. Circ J. 2023;87:629–39.CrossRefPubMed
53.
go back to reference Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al. Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN). Circ J. 2023;87:857–65.CrossRefPubMed Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al. Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN). Circ J. 2023;87:857–65.CrossRefPubMed
54.
go back to reference Nakatani S, Sotomi Y, Suzuki S, Kobayashi T, Hamanaka Y, Omatsu T, et al. Angioscopic comparison of early- and mid-term vascular responses following treatment of ST-elevation acute myocardial infarction with biodegradable vs. durable polymer everolimus-eluting stents—a prespecified subanalysis of the MECHANISM AMI RCT. Circ J. 2023;87:619–28.CrossRefPubMed Nakatani S, Sotomi Y, Suzuki S, Kobayashi T, Hamanaka Y, Omatsu T, et al. Angioscopic comparison of early- and mid-term vascular responses following treatment of ST-elevation acute myocardial infarction with biodegradable vs. durable polymer everolimus-eluting stents—a prespecified subanalysis of the MECHANISM AMI RCT. Circ J. 2023;87:619–28.CrossRefPubMed
55.
go back to reference Natsuaki M, Morimoto T, Iimuro S, Fujita R, Iwata H, Miyauchi K, et al. Thrombotic risk stratification and intensive statin therapy for secondary prevention of coronary artery disease—insights from the REAL-CAD study. Circ J. 2022;86:1416–27.CrossRefPubMed Natsuaki M, Morimoto T, Iimuro S, Fujita R, Iwata H, Miyauchi K, et al. Thrombotic risk stratification and intensive statin therapy for secondary prevention of coronary artery disease—insights from the REAL-CAD study. Circ J. 2022;86:1416–27.CrossRefPubMed
56.
go back to reference Ohashi J, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Watanabe Y, et al. Comparison of long-term clinical outcomes in patients stratified by a novel acute myocardial infarction risk stratification (nARS) system. Circ J. 2022;86:1519–26.CrossRefPubMed Ohashi J, Sakakura K, Jinnouchi H, Taniguchi Y, Tsukui T, Watanabe Y, et al. Comparison of long-term clinical outcomes in patients stratified by a novel acute myocardial infarction risk stratification (nARS) system. Circ J. 2022;86:1519–26.CrossRefPubMed
57.
go back to reference Okamoto H, Nishi T, Ishii M, Tsujita K, Koto S, Nakai M, et al. Clinical characteristics and outcomes of patients presenting with acute myocardial infarction without cardiogenic shock. Circ J. 2022;86:1527–38.CrossRefPubMed Okamoto H, Nishi T, Ishii M, Tsujita K, Koto S, Nakai M, et al. Clinical characteristics and outcomes of patients presenting with acute myocardial infarction without cardiogenic shock. Circ J. 2022;86:1527–38.CrossRefPubMed
58.
go back to reference Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Okubo M, et al. Diagnostic accuracy of artificial intelligence-based angiography-derived fractional flow reserve using pressure wire-based fractional flow reserve as a reference. Circ J. 2023;87:783–90.CrossRefPubMed Omori H, Kawase Y, Mizukami T, Tanigaki T, Hirata T, Okubo M, et al. Diagnostic accuracy of artificial intelligence-based angiography-derived fractional flow reserve using pressure wire-based fractional flow reserve as a reference. Circ J. 2023;87:783–90.CrossRefPubMed
59.
go back to reference Roh JW, Bae S, Johnson TW, Heo SJ, Kim Y, Cho DK, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with acute myocardial infarction and chronic kidney disease. Circ J. 2023;87:1339–46.CrossRefPubMed Roh JW, Bae S, Johnson TW, Heo SJ, Kim Y, Cho DK, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention in patients with acute myocardial infarction and chronic kidney disease. Circ J. 2023;87:1339–46.CrossRefPubMed
60.
go back to reference Sasaki K, Koeda Y, Yoshizawa R, Ishikawa Y, Ishida M, Itoh T, et al. Comparing in-hospital outcomes for acute myocardial infarction patients in high-volume hospitals performing primary percutaneous coronary intervention vs. regional general hospitals. Circ J. 2023;87:1347–55.CrossRefPubMed Sasaki K, Koeda Y, Yoshizawa R, Ishikawa Y, Ishida M, Itoh T, et al. Comparing in-hospital outcomes for acute myocardial infarction patients in high-volume hospitals performing primary percutaneous coronary intervention vs. regional general hospitals. Circ J. 2023;87:1347–55.CrossRefPubMed
61.
go back to reference Sawayama Y, Tomita Y, Kohyama S, Higo Y, Kodama K, Asada K, et al. Clopidogrel use in CYP2C19 loss-of-function carriers with high bleeding risk after percutaneous coronary intervention. Circ J. 2023;87:755–63.CrossRefPubMed Sawayama Y, Tomita Y, Kohyama S, Higo Y, Kodama K, Asada K, et al. Clopidogrel use in CYP2C19 loss-of-function carriers with high bleeding risk after percutaneous coronary intervention. Circ J. 2023;87:755–63.CrossRefPubMed
63.
go back to reference Suzuki N, Yokoi T, Kimura T, Ikeda Y, Takahashi S, Aoyagi T, et al. Prediction of slow-flow phenomenon after stent implantation using near-infrared spectroscopy in patients with acute and chronic coronary syndrome. Circ J. 2024;88:972–9.CrossRefPubMed Suzuki N, Yokoi T, Kimura T, Ikeda Y, Takahashi S, Aoyagi T, et al. Prediction of slow-flow phenomenon after stent implantation using near-infrared spectroscopy in patients with acute and chronic coronary syndrome. Circ J. 2024;88:972–9.CrossRefPubMed
64.
go back to reference Takagi R, Kubo T. Clinical value of optical coherence tomography in guiding bifurcation percutaneous coronary intervention. Circ J. 2024;88:970–1.CrossRefPubMed Takagi R, Kubo T. Clinical value of optical coherence tomography in guiding bifurcation percutaneous coronary intervention. Circ J. 2024;88:970–1.CrossRefPubMed
65.
go back to reference Takeji Y, Morimoto T, Shiomi H, Kato ET, Imada K, Yoshikawa Y, et al. Sex differences in clinical outcomes after percutaneous coronary intervention. Circ J. 2023;87:277–86.CrossRefPubMed Takeji Y, Morimoto T, Shiomi H, Kato ET, Imada K, Yoshikawa Y, et al. Sex differences in clinical outcomes after percutaneous coronary intervention. Circ J. 2023;87:277–86.CrossRefPubMed
66.
go back to reference Ueda Y. Slow-flow phenomenon caused by distal embolization should be predicted and prevented to maximize the efficacy of coronary intervention. Circ J. 2024;88:980–1.CrossRefPubMed Ueda Y. Slow-flow phenomenon caused by distal embolization should be predicted and prevented to maximize the efficacy of coronary intervention. Circ J. 2024;88:980–1.CrossRefPubMed
67.
go back to reference Ueno H, Hoshino M, Usui E, Sugiyama T, Kanaji Y, Hada M, et al. Prognostic implications of fractional flow reserve and coronary flow reserve after drug-eluting stent implantation. Circ J. 2024;88:853–9.CrossRefPubMed Ueno H, Hoshino M, Usui E, Sugiyama T, Kanaji Y, Hada M, et al. Prognostic implications of fractional flow reserve and coronary flow reserve after drug-eluting stent implantation. Circ J. 2024;88:853–9.CrossRefPubMed
68.
go back to reference Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Natsuaki M, Yamaji K, et al. Prevalence and effects of high-intensity statins for japanese patients presenting with acute coronary syndrome—a post hoc secondary analysis of STOPDAPT-2 ACS. Circ J. 2023;87:657–68.CrossRefPubMed Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Natsuaki M, Yamaji K, et al. Prevalence and effects of high-intensity statins for japanese patients presenting with acute coronary syndrome—a post hoc secondary analysis of STOPDAPT-2 ACS. Circ J. 2023;87:657–68.CrossRefPubMed
69.
go back to reference Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Nakamura S, et al. Dual antiplatelet therapy duration after multivessel optimal intravascular ultrasound-guided percutaneous coronary intervention. Circ J. 2023;87:1661–71.CrossRefPubMed Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Nakamura S, et al. Dual antiplatelet therapy duration after multivessel optimal intravascular ultrasound-guided percutaneous coronary intervention. Circ J. 2023;87:1661–71.CrossRefPubMed
71.
go back to reference Yufu K, Shimomura T, Kawano K, Sato H, Yonezu K, Saito S, et al. Usefulness of prehospital 12-lead electrocardiography system in ST-segment elevation myocardial infarction patients in Oita—comparison between urban and rural areas, weekday daytime and weekday nighttime/holidays. Circ J. 2023. https://doi.org/10.1253/circj.CJ-23-0365.CrossRefPubMed Yufu K, Shimomura T, Kawano K, Sato H, Yonezu K, Saito S, et al. Usefulness of prehospital 12-lead electrocardiography system in ST-segment elevation myocardial infarction patients in Oita—comparison between urban and rural areas, weekday daytime and weekday nighttime/holidays. Circ J. 2023. https://​doi.​org/​10.​1253/​circj.​CJ-23-0365.CrossRefPubMed
72.
go back to reference Yamamoto K, Morimoto T, Natsuaki M, Shiomi H, Ozasa N, Sakamoto H, et al. Polypharmacy and bleeding outcomes after percutaneous coronary intervention. Circ J. 2024;88:888–99.CrossRefPubMed Yamamoto K, Morimoto T, Natsuaki M, Shiomi H, Ozasa N, Sakamoto H, et al. Polypharmacy and bleeding outcomes after percutaneous coronary intervention. Circ J. 2024;88:888–99.CrossRefPubMed
73.
go back to reference Avis SR, Vernon ST, Hagström E, Figtree GA. Coronary artery disease in the absence of traditional risk factors: a call for action. Eur Heart J. 2021;42:3822–4.CrossRefPubMed Avis SR, Vernon ST, Hagström E, Figtree GA. Coronary artery disease in the absence of traditional risk factors: a call for action. Eur Heart J. 2021;42:3822–4.CrossRefPubMed
74.
go back to reference Geng L, Shi X, Yuan Y, Du P, Gao L, Wang Y, et al. Anatomical and functional discrepancy in diabetic patients with intermediate coronary lesions—an intravascular ultrasound and quantitative flow ratio study. Circ J. 2023;87:320–8.CrossRefPubMed Geng L, Shi X, Yuan Y, Du P, Gao L, Wang Y, et al. Anatomical and functional discrepancy in diabetic patients with intermediate coronary lesions—an intravascular ultrasound and quantitative flow ratio study. Circ J. 2023;87:320–8.CrossRefPubMed
75.
go back to reference Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, et al. Residual coronary risk factors associated with long-term clinical outcomes in patients with coronary artery disease treated with high- vs. low-dose statin therapy—REAL-CAD substudy. Circ J. 2024;88:995–1003.CrossRefPubMed Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, et al. Residual coronary risk factors associated with long-term clinical outcomes in patients with coronary artery disease treated with high- vs. low-dose statin therapy—REAL-CAD substudy. Circ J. 2024;88:995–1003.CrossRefPubMed
76.
go back to reference Hisamatsu T, Kinuta M. Long-term effect of smoking ban legislation on hospitalization for acute coronary syndrome. Circ J. 2023;87:1686–8.CrossRefPubMed Hisamatsu T, Kinuta M. Long-term effect of smoking ban legislation on hospitalization for acute coronary syndrome. Circ J. 2023;87:1686–8.CrossRefPubMed
77.
go back to reference Kiyosue A, Yasuda S, Tomura A, Usami M, Arai H. Safety and effectiveness of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in patients with familial or non-familial hypercholesterolemia—a post-marketing survey (J-POSSIBLE). Circ J. 2023;87:834–46.CrossRefPubMed Kiyosue A, Yasuda S, Tomura A, Usami M, Arai H. Safety and effectiveness of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in patients with familial or non-familial hypercholesterolemia—a post-marketing survey (J-POSSIBLE). Circ J. 2023;87:834–46.CrossRefPubMed
78.
go back to reference Nakai M, Iwanaga Y, Sumita Y, Amano T, Fukuda I, Hirano T, et al. Long-term follow-up study of hospitalizations for acute coronary syndrome in kobe-city and other districts under the Hyogo smoking ban legislation—a nationwide database study. Circ J. 2023;87:1680–5.CrossRefPubMed Nakai M, Iwanaga Y, Sumita Y, Amano T, Fukuda I, Hirano T, et al. Long-term follow-up study of hospitalizations for acute coronary syndrome in kobe-city and other districts under the Hyogo smoking ban legislation—a nationwide database study. Circ J. 2023;87:1680–5.CrossRefPubMed
79.
go back to reference Ogura M. Is high-density lipoprotein functionality useful as a residual risk marker for familial hypercholesterolemia? Circ J. 2023;87:813–4.CrossRefPubMed Ogura M. Is high-density lipoprotein functionality useful as a residual risk marker for familial hypercholesterolemia? Circ J. 2023;87:813–4.CrossRefPubMed
80.
81.
go back to reference Tada H, Okada H, Nohara A, Toh R, Harada A, Murakami K, et al. Impact of high-density lipoprotein function, rather than high-density lipoprotein cholesterol level, on cardiovascular disease among patients with familial hypercholesterolemia. Circ J. 2023;87:806–12.CrossRefPubMed Tada H, Okada H, Nohara A, Toh R, Harada A, Murakami K, et al. Impact of high-density lipoprotein function, rather than high-density lipoprotein cholesterol level, on cardiovascular disease among patients with familial hypercholesterolemia. Circ J. 2023;87:806–12.CrossRefPubMed
82.
go back to reference Takeuchi F, Takano K, Yamamoto M, Isono M, Miyake W, Mori K, et al. Clinical implication of smoking-related aryl-hydrocarbon receptor repressor (AHRR) hypomethylation in japanese adults. Circ J. 2022;86:986–92.CrossRefPubMed Takeuchi F, Takano K, Yamamoto M, Isono M, Miyake W, Mori K, et al. Clinical implication of smoking-related aryl-hydrocarbon receptor repressor (AHRR) hypomethylation in japanese adults. Circ J. 2022;86:986–92.CrossRefPubMed
83.
go back to reference Toyota T, Morimoto T, Iimuro S, Fujita R, Iwata H, Miyauchi K, et al. Low-density lipoprotein cholesterol levels on statins and cardiovascular event risk in stable coronary artery disease—an observation from the REAL-CAD study. Circ J. 2023;87:360–7.CrossRefPubMed Toyota T, Morimoto T, Iimuro S, Fujita R, Iwata H, Miyauchi K, et al. Low-density lipoprotein cholesterol levels on statins and cardiovascular event risk in stable coronary artery disease—an observation from the REAL-CAD study. Circ J. 2023;87:360–7.CrossRefPubMed
84.
go back to reference Zhan R, Zhang J, Chen X, Liu T, He Y, Zhang S, et al. Targeting the efficacy of intensive blood pressure treatment in hypertensive patients—an exploratory analysis of SPRINT. Circ J. 2023;87:1212–8.CrossRefPubMed Zhan R, Zhang J, Chen X, Liu T, He Y, Zhang S, et al. Targeting the efficacy of intensive blood pressure treatment in hypertensive patients—an exploratory analysis of SPRINT. Circ J. 2023;87:1212–8.CrossRefPubMed
85.
go back to reference Kong G, Chin YH, Chong B, Goh RSJ, Lim OZH, Ng CH, et al. Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients. Int J Cardiol. 2023;371:432–40.CrossRefPubMed Kong G, Chin YH, Chong B, Goh RSJ, Lim OZH, Ng CH, et al. Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients. Int J Cardiol. 2023;371:432–40.CrossRefPubMed
86.
go back to reference Figtree GA, Vernon ST, Harmer JA, Gray MP, Arnott C, Bachour E, et al. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC state-of-the-art review. J Am Coll Cardiol. 2023;82:1343–59.PubMedCentralCrossRefPubMed Figtree GA, Vernon ST, Harmer JA, Gray MP, Arnott C, Bachour E, et al. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC state-of-the-art review. J Am Coll Cardiol. 2023;82:1343–59.PubMedCentralCrossRefPubMed
87.
go back to reference Abe S, Haruyama Y, Kobashi G, Toyoda S, Inoue T, Tomiyama H, et al. Effect of novel stratified lipid risk by “LDL-Window” and flow-mediated dilation on the prognosis of coronary artery disease using the FMD-J study a data. Circ J. 2022;86:1444–54.CrossRefPubMed Abe S, Haruyama Y, Kobashi G, Toyoda S, Inoue T, Tomiyama H, et al. Effect of novel stratified lipid risk by “LDL-Window” and flow-mediated dilation on the prognosis of coronary artery disease using the FMD-J study a data. Circ J. 2022;86:1444–54.CrossRefPubMed
88.
go back to reference Ashikawa H, Adachi T, Iwatsu K, Kamisaka K, Kamiya K, Uchiyama Y, et al. Physical frailty may predict 2-year prognosis in elderly patients with acute myocardial infarction—a report from the FLAGSHIP study. Circ J. 2023;87:490–7.CrossRefPubMed Ashikawa H, Adachi T, Iwatsu K, Kamisaka K, Kamiya K, Uchiyama Y, et al. Physical frailty may predict 2-year prognosis in elderly patients with acute myocardial infarction—a report from the FLAGSHIP study. Circ J. 2023;87:490–7.CrossRefPubMed
90.
go back to reference Iijima R. Polypharmacy as new risk factor of major bleeding in patients undergoing coronary stent implantation—which come first, the chicken or the egg? Circ J. 2024;88:900–1.CrossRefPubMed Iijima R. Polypharmacy as new risk factor of major bleeding in patients undergoing coronary stent implantation—which come first, the chicken or the egg? Circ J. 2024;88:900–1.CrossRefPubMed
91.
go back to reference Ikenaga H, Nakano Y. Importance of the assessment of physical frailty in elderly Japanese patients with acute myocardial infarction. Circ J. 2023;87:498–9.CrossRefPubMed Ikenaga H, Nakano Y. Importance of the assessment of physical frailty in elderly Japanese patients with acute myocardial infarction. Circ J. 2023;87:498–9.CrossRefPubMed
92.
go back to reference Ishii H. Acute coronary syndrome and cancer—cardio-oncology in the super aged society in Japan. Circ J. 2024;88:215–6.CrossRefPubMed Ishii H. Acute coronary syndrome and cancer—cardio-oncology in the super aged society in Japan. Circ J. 2024;88:215–6.CrossRefPubMed
93.
go back to reference Kadowaki H, Akazawa H, Shindo A, Ueda T, Ishida J, Komuro I. Shared and reciprocal mechanisms between heart failure and cancer—an emerging concept of heart-cancer axis. Circ J. 2024;88:182–8.CrossRefPubMed Kadowaki H, Akazawa H, Shindo A, Ueda T, Ishida J, Komuro I. Shared and reciprocal mechanisms between heart failure and cancer—an emerging concept of heart-cancer axis. Circ J. 2024;88:182–8.CrossRefPubMed
94.
go back to reference Kobayashi T, Kitahara H, Kato K, Saito Y, Kobayashi Y. Impact of parathyroid hormone level on intracoronary calcification and short- and long-term outcomes in dialysis patients undergoing percutaneous coronary intervention. Circ J. 2023;87:247–55.CrossRefPubMed Kobayashi T, Kitahara H, Kato K, Saito Y, Kobayashi Y. Impact of parathyroid hormone level on intracoronary calcification and short- and long-term outcomes in dialysis patients undergoing percutaneous coronary intervention. Circ J. 2023;87:247–55.CrossRefPubMed
95.
go back to reference Mizuno A, Kaneko H, Suzuki Y, Okada A, Takeda N, Morita H, et al. Enduring relevance of the stages of change model for transforming lifestyle behaviors. Circ J. 2023;87:1138–42.CrossRefPubMed Mizuno A, Kaneko H, Suzuki Y, Okada A, Takeda N, Morita H, et al. Enduring relevance of the stages of change model for transforming lifestyle behaviors. Circ J. 2023;87:1138–42.CrossRefPubMed
96.
go back to reference Numasawa Y. Impact of platelet reactivity on ischemic and bleeding events after percutaneous coronary intervention—a long-term perspective. Circ J. 2022;86:1350–1.CrossRefPubMed Numasawa Y. Impact of platelet reactivity on ischemic and bleeding events after percutaneous coronary intervention—a long-term perspective. Circ J. 2022;86:1350–1.CrossRefPubMed
97.
go back to reference Otsuki H, Yamaguchi J. Intact parathyroid hormone in hemodialysis patients undergoing percutaneous coronary intervention—is it just a marker or a diamond in the rough? Circ J. 2023;87:256–7.CrossRefPubMed Otsuki H, Yamaguchi J. Intact parathyroid hormone in hemodialysis patients undergoing percutaneous coronary intervention—is it just a marker or a diamond in the rough? Circ J. 2023;87:256–7.CrossRefPubMed
98.
go back to reference Suzuki T, Mizuno A, Yasui H, Noma S, Ohmori T, Rewley J, et al. Scoping review of screening and assessment tools for social determinants of health in the field of cardiovascular disease. Circ J. 2024;88:390–407.CrossRefPubMed Suzuki T, Mizuno A, Yasui H, Noma S, Ohmori T, Rewley J, et al. Scoping review of screening and assessment tools for social determinants of health in the field of cardiovascular disease. Circ J. 2024;88:390–407.CrossRefPubMed
99.
go back to reference Takei Y, Tomiyama H, Higashi Y, Yamashina A, Chikamori T. Association between endothelial dysfunction and left ventricular diastolic stiffness—subanalysis of the flow-mediated dilation Japan (FMD-J) study. Circ J. 2023;87:1203–11.CrossRefPubMed Takei Y, Tomiyama H, Higashi Y, Yamashina A, Chikamori T. Association between endothelial dysfunction and left ventricular diastolic stiffness—subanalysis of the flow-mediated dilation Japan (FMD-J) study. Circ J. 2023;87:1203–11.CrossRefPubMed
100.
go back to reference Takeuchi T, Kosugi S, Ueda Y, Ikeoka K, Yamane H, Takayasu K, et al. Impact of a cancer history on cardiovascular events among patients with myocardial infarction who received revascularization. Circ J. 2024;88:207–14.CrossRefPubMed Takeuchi T, Kosugi S, Ueda Y, Ikeoka K, Yamane H, Takayasu K, et al. Impact of a cancer history on cardiovascular events among patients with myocardial infarction who received revascularization. Circ J. 2024;88:207–14.CrossRefPubMed
101.
go back to reference Tamura Y, Tamura Y, Taniguchi H, Imanaka-Yoshida K. Acute myocarditis after discontinuation of immune checkpoint inhibitor therapy. Circ J. 2023;87:376.CrossRefPubMed Tamura Y, Tamura Y, Taniguchi H, Imanaka-Yoshida K. Acute myocarditis after discontinuation of immune checkpoint inhibitor therapy. Circ J. 2023;87:376.CrossRefPubMed
102.
go back to reference Tokeshi T, Date A, Miura H, Kumasaka L, Arakawa T, Nakao K, et al. Predictors of improvement in exercise capacity after cardiac rehabilitation differ between octogenarian and young-old patients with acute myocardial infarction. Circ J. 2023;87:815–23.CrossRefPubMed Tokeshi T, Date A, Miura H, Kumasaka L, Arakawa T, Nakao K, et al. Predictors of improvement in exercise capacity after cardiac rehabilitation differ between octogenarian and young-old patients with acute myocardial infarction. Circ J. 2023;87:815–23.CrossRefPubMed
103.
go back to reference Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu arteritis—evidence from a national registry analysis. Circ J. 2024;88:285–94.CrossRefPubMed Yoshifuji H, Nakaoka Y, Uchida HA, Sugihara T, Watanabe Y, Funakoshi S, et al. Organ damage and quality of life in Takayasu arteritis—evidence from a national registry analysis. Circ J. 2024;88:285–94.CrossRefPubMed
104.
go back to reference Zhang Y, Hao W, Fan J, Guo R, Ai H, Que B, et al. Association between obstructive sleep apnea and cardiovascular events in acute coronary syndrome patients with or without revascularization—a prospective cohort study. Circ J. 2023;87:1369–79.CrossRefPubMed Zhang Y, Hao W, Fan J, Guo R, Ai H, Que B, et al. Association between obstructive sleep apnea and cardiovascular events in acute coronary syndrome patients with or without revascularization—a prospective cohort study. Circ J. 2023;87:1369–79.CrossRefPubMed
105.
go back to reference Makita S, Yasu T, Akashi YJ, Adachi H, Izawa H, Ishihara S, et al. JCS/JACR 2021 guideline on rehabilitation in patients with cardiovascular disease. Circ J. 2022;87:155–235.CrossRefPubMed Makita S, Yasu T, Akashi YJ, Adachi H, Izawa H, Ishihara S, et al. JCS/JACR 2021 guideline on rehabilitation in patients with cardiovascular disease. Circ J. 2022;87:155–235.CrossRefPubMed
107.
go back to reference Matsumoto T, Saito Y, Yamashita D, Sato T, Wakabayashi S, Kitahara H, et al. Impact of active and historical cancer on short- and long-term outcomes in patients with acute myocardial infarction. Am J Cardiol. 2021;159:59–64.CrossRefPubMed Matsumoto T, Saito Y, Yamashita D, Sato T, Wakabayashi S, Kitahara H, et al. Impact of active and historical cancer on short- and long-term outcomes in patients with acute myocardial infarction. Am J Cardiol. 2021;159:59–64.CrossRefPubMed
108.
go back to reference Yaginuma H, Saito Y, Sato T, Yamashita D, Matsumoto T, Suzuki S, et al. Clinical characteristics and outcomes of patients with chronic systemic inflammatory disease in acute myocardial infarction. PLoS ONE. 2023;18: e0289794.PubMedCentralCrossRefPubMed Yaginuma H, Saito Y, Sato T, Yamashita D, Matsumoto T, Suzuki S, et al. Clinical characteristics and outcomes of patients with chronic systemic inflammatory disease in acute myocardial infarction. PLoS ONE. 2023;18: e0289794.PubMedCentralCrossRefPubMed
109.
go back to reference Reindl M, Stiermaier T, Lechner I, Tiller C, Holzknecht M, Fink P, et al. Infarct severity and outcomes in ST-elevation myocardial infarction patients without standard modifiable risk factors—a multicenter cardiac magnetic resonance study. Eur J Intern Med. 2024;119:78–83.CrossRefPubMed Reindl M, Stiermaier T, Lechner I, Tiller C, Holzknecht M, Fink P, et al. Infarct severity and outcomes in ST-elevation myocardial infarction patients without standard modifiable risk factors—a multicenter cardiac magnetic resonance study. Eur J Intern Med. 2024;119:78–83.CrossRefPubMed
110.
go back to reference Mazhar J, Figtree G, Vernon ST, Galougahi KK, Carlo J, Nissen SE, et al. Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol. 2020;4: 100116.PubMedCentralCrossRefPubMed Mazhar J, Figtree G, Vernon ST, Galougahi KK, Carlo J, Nissen SE, et al. Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol. 2020;4: 100116.PubMedCentralCrossRefPubMed
111.
go back to reference Mazhar J, Ekstrom K, Kozor R, Grieve SM, Nepper-Christensen L, Ahtarovski KA, et al. Cardiovascular magnetic resonance characteristics and clinical outcomes of patients with ST-elevation myocardial infarction and no standard modifiable risk factors-A DANAMI-3 substudy. Front Cardiovasc Med. 2022;9: 945815.PubMedCentralCrossRefPubMed Mazhar J, Ekstrom K, Kozor R, Grieve SM, Nepper-Christensen L, Ahtarovski KA, et al. Cardiovascular magnetic resonance characteristics and clinical outcomes of patients with ST-elevation myocardial infarction and no standard modifiable risk factors-A DANAMI-3 substudy. Front Cardiovasc Med. 2022;9: 945815.PubMedCentralCrossRefPubMed
112.
113.
go back to reference Herrett E, Bhaskaran K, Timmis A, Denaxas S, Hemingway H, Smeeth L. Association between clinical presentations before myocardial infarction and coronary mortality: a prospective population-based study using linked electronic records. Eur Heart J. 2014;35:2363–71.PubMedCentralCrossRefPubMed Herrett E, Bhaskaran K, Timmis A, Denaxas S, Hemingway H, Smeeth L. Association between clinical presentations before myocardial infarction and coronary mortality: a prospective population-based study using linked electronic records. Eur Heart J. 2014;35:2363–71.PubMedCentralCrossRefPubMed
114.
go back to reference Kanaoka K, Iwanaga Y, Okada K, Terasaki S, Nishioka Y, Nakai M, et al. Validity of diagnostic algorithms for cardiovascular diseases in Japanese health insurance claims. Circ J. 2023;87:536–42.CrossRefPubMed Kanaoka K, Iwanaga Y, Okada K, Terasaki S, Nishioka Y, Nakai M, et al. Validity of diagnostic algorithms for cardiovascular diseases in Japanese health insurance claims. Circ J. 2023;87:536–42.CrossRefPubMed
115.
go back to reference Moysidis DV, Daios S, Anastasiou V, Liatsos AC, Papazoglou AS, Karagiannidis E, et al. Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors—rationale and design of the “Beyond-SMuRFs Study.” BMC Cardiovasc Disord. 2023;23:149.PubMedCentralCrossRefPubMed Moysidis DV, Daios S, Anastasiou V, Liatsos AC, Papazoglou AS, Karagiannidis E, et al. Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors—rationale and design of the “Beyond-SMuRFs Study.” BMC Cardiovasc Disord. 2023;23:149.PubMedCentralCrossRefPubMed
116.
go back to reference Smilowitz NR, Mahajan AM, Roe MT, Hellkamp AS, Chiswell K, Gulati M, et al. Mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG (acute coronary treatment and intervention outcomes network registry-get with the guidelines). Circ Cardiovasc Qual Outcomes. 2017;10: e003443.CrossRefPubMed Smilowitz NR, Mahajan AM, Roe MT, Hellkamp AS, Chiswell K, Gulati M, et al. Mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG (acute coronary treatment and intervention outcomes network registry-get with the guidelines). Circ Cardiovasc Qual Outcomes. 2017;10: e003443.CrossRefPubMed
117.
go back to reference Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et al. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302:874–82.PubMedCentralCrossRefPubMed Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et al. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302:874–82.PubMedCentralCrossRefPubMed
118.
go back to reference Oba Y, Kabutoya T, Kohro T, Imai Y, Kario K, Sato H, et al. Relationships among heart rate, beta-blocker dosage, and prognosis in patients with coronary artery disease in a real-world database using a multimodal data acquisition system. Circ J. 2023;87:336–44.CrossRefPubMed Oba Y, Kabutoya T, Kohro T, Imai Y, Kario K, Sato H, et al. Relationships among heart rate, beta-blocker dosage, and prognosis in patients with coronary artery disease in a real-world database using a multimodal data acquisition system. Circ J. 2023;87:336–44.CrossRefPubMed
Metadata
Title
No standard modifiable cardiovascular risk factors in acute myocardial infarction: prevalence, pathophysiology, and prognosis
Authors
Yuichi Saito
Kenichi Tsujita
Yoshio Kobayashi
Publication date
17-06-2024
Publisher
Springer Nature Singapore
Published in
Cardiovascular Intervention and Therapeutics
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-024-01022-4
Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine